Speaker Profile
Co-founder, CSO, Weave Bio
Biography
Ari is Cofounder and CSO at Weave Bio. Weaves native-AI regulatory platform helps life science companies to weave together data and documentation for all regulatory submissions, from pre-IND to NDABLA, directly from the source data and studies. Previously, Ari was the first Chief Analytics Officer at Memorial Sloan Kettering Cancer Center (MSK) where he drove pioneering efforts using clinical data to analyze patient outcomes. Aris team at MSK developed the first operational AI model to match patients to clinical trials. While at MSK, Ari also contributed to the creation of startups like Flatiron Health and Paige AI. In 2019, Ari cofounded Daat. AI which was acquired by Tempus AI, where Ari served as SVP of RWD.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• John Quackenbush, Harvard
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Foundation Models of Human Cancer Biology to Predict Clinical Outcomes
• Ron Alfa, Noetik
Mechanistic Modeling of the Human Immune System: A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, CytoReason
Biological Foundation Models: Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
From Prediction to Translation: AI and In Vivo Validation to Improve Drug Development Success
• Gabriel Musso, BioSymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development and Advancing Precision Medicine
• Chair: Shivanni Kummar, PATHOMIQ
• Dale Muzzey, Myriad Genetics
• Sanoj Punnen, University of Miami
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug? Closing the Loop from Drug Discovery to Development
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI: From Genomic Data to Therapeutic Insights
• Lisa Gurry, GeneDx
Limited Sample Models for Faster Lead Discovery, High Accuracy, and Regulatory Grade AI
• Lalin Theverapperuma, Expert Intelligence
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
